Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI could predict which stomach cancer patients benefit from Pre-Surgery therapy

NCT ID NCT07401199

Diagnosis Sponsor: Qun Zhao Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is developing an artificial intelligence (AI) system to predict how well gastric cancer will respond to chemotherapy and immunotherapy given before surgery. Researchers will collect data from 2,000 patients with locally advanced gastric cancer. The AI will analyze standard CT scans and tissue samples to forecast if the tumor will completely disappear after treatment. If accurate, this tool could help doctors choose the best treatment for each patient.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Artificial intelligence system (DeepComp) analyzing CT images and pathology slides
What this could lead to
If successful, this AI tool could help doctors personalize treatment plans for gastric cancer patients, avoiding unnecessary side effects.
What could go wrong
This is an observational study to develop and validate the AI model, not a treatment trial. The AI may not be accurate enough for real-world use, and results are still early.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 2,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with locally advanced gastric cancer who are admitted to the participating centers and are scheduled to undergo neoadjuvant chemo-immunotherapy according to real-world clinical practice.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Age ≥ 18 years. Histologically confirmed gastric or gastroesophageal junction adenocarcinoma. Clinical stage cT3-4a, N+, M0 (locally advanced) assessed by CT/MRI and endoscopic ultrasound. Scheduled to receive neoadjuvant chemotherapy combined with PD-1 inhibitors (regimens including but not limited to SOX/XELOX + Sintilimab/Tislelizumab/Camrelizumab, etc.) as standard of care. Availability of standard pre-treatment contrast-enhanced abdominal CT images. Willingness to provide peripheral blood samples and tumor tissue (biopsy/surgical) for sequencing and analysis. ECOG performance status 0-1. Adequate organ function to tolerate systemic chemotherapy. Exclusion Criteria: Evidence of distant metastasis (Stage IV) or unresectable disease. Previous systemic anti-tumor therapy for gastric cancer (chemotherapy, radiotherapy, or immunotherapy). History of other malignancies within the past 5 years. Active autoimmune diseases requiring systemic immunosuppressive treatment (contraindication for PD-1 inhibitors). Emergency surgery due to obstruction, perforation, or uncontrolled bleeding. Severe metallic artifacts on CT images that interfere with radiomic feature extraction. Pregnancy or lactation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastric cancer (GC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

gastric cancer gastric neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastric cancer (GC) Locally advanced gastric cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    9 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Baoding Central Hospital

    RECRUITING

    Baoding, None Selected, 050011, China

  • Cangzhou People's Hospital

    RECRUITING

    Cangzhou, Hebei, 050011, China

  • Hengshui People's Hospital

    RECRUITING

    Hengshui, Hebei, 053099, China

  • Renmin Hospital of Wuhan University

    RECRUITING

    Wuhan, Hubei, 430065, China

  • Shijiazhuang People's Hospital

    RECRUITING

    Shijiazhuang, None Selected, 050011, China

  • The Fifth Affiliated Hospital of Anhui Medical University

    RECRUITING

    Fuyang, Anhui, 050011, China

  • The Second Affiliated Hospital of Xingtai Medical College

    RECRUITING

    Xingtai, Hebei, 050011, China

  • Yichang Central Hospital

    RECRUITING

    Yichang, Hubei, 448000, China

  • the Fourth Hospital of Hebei Medical University

    RECRUITING

    Shijiazhuang, None Selected, 050011, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.